These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study.
    Author: Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, Kristiansen G, Müller SC, Ellinger J.
    Journal: Anticancer Res; 2014 Feb; 34(2):665-9. PubMed ID: 24510997.
    Abstract:
    BACKGROUND/AIM: Increased levels of microRNAs in serum/plasma have been identified in various malignancies. We aimed to investigate serum levels of miR-26a-1 and miR-141 in patients undergoing prostate biopsy clinical suspicious for prostate cancer (PCA) in a prospective multi-center study. PATIENTS AND METHODS: Pre-biopsy serum samples of 170 patients were collected in three different study Centres. Serum RNA was isolated, and microRNA lev-els were quantified using real-time PCR. Relative miR-26a -1 and miR-141 levels were determined using RNU1-4 and SNORD43 as reference genes. RESULTS: After exclusion of pa-tients with metastatic prostate cancer (n=9) and isolation failures (n=28), 133 patients (prostate cancer n=54, non-malignant n=79) were used for further analysis. The levels of miR-26a-1 and miR-141 were similar in patients with positive and negative biopsies. We observed a significant increase of miR-141 in patients with higher Gleason Score. CONCLUSION: The analysis of circulating microRNAs does not seem to help identify patients with cancer undergoing prostate biopsy. However, their levels may be useful to identify patients with high-risk prostate cancer.
    [Abstract] [Full Text] [Related] [New Search]